CSTF2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 3.41948691584548E-14 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
6.21650000365292E-08 |
Normal-vs-Stage2 |
1.398830E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
3.616200E-03 |
Stage1-vs-Stage2 |
5.339600E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
8.313800E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
4.929400E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
1.01869623847506E-11 |
Normal-vs-AfricanAmerican |
1.779590E-01 |
Normal-vs-Asian |
7.724400E-03 |
Caucasian-vs-AfricanAmerican |
1.907630E-01 |
Caucasian-vs-Asian |
1.846040E-01 |
AfricanAmerican-vs-Asian |
8.051600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.21710000000608E-06 |
Normal-vs-Female |
8.19580003863507E-09 |
Male-vs-Female |
6.444400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
3.221100E-03 |
Normal-vs-Extreme_Weight |
1.28639999763536E-08 |
Normal-vs-Obese |
4.006600E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
1.895600E-01 |
Normal_Weight-vs-Obese |
6.153800E-02 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
1.365030E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
5.935700E-02 |
Normal-vs-Age(41-60Yrs) |
2.415600E-04 |
Normal-vs-Age(61-80Yrs) |
5.89110005222437E-09 |
Normal-vs-Age(81-100Yrs) |
1.481570E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.244800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.869400E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.985400E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.985400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.409600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.768200E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
2.431600E-01 |
Normal-vs-Grade 3 |
5.547600E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
9.736100E-02 |
Grade 2-vs-Grade 4 |
2.431600E-01 |
Grade 3-vs-Grade 4 |
5.547600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.02630126619374E-11 |
Normal-vs-N1 |
5.844800E-04 |
N0-vs-N1 |
1.557990E-02 |
|
|